Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 15, 2015 - Issue 4
Submit an article Journal homepage
369
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study

Alfredo CarratoHospital Universitario Ramón y Cajal, Madrid, Spain
,
Pilar GarcíaHospital General Universitario Gregorio Marañón, Madrid, Spain
,
Rafael LópezComplejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain
,
Teresa MacarullaHospital Universitari Vall d’Hebrón, Universitat Autònoma de Barcelona, Barcelona, Spain
,
Fernando RiveraHospital Universitario Marqués de Valdecilla, Santander, Spain
,
Javier SastreHospital Clínico San Carlos, Center affiliated to the Red Temática de Investigación Cooperativa (RD06/0020/0021). Instituto Carlos III, Spanish Ministry of Science and Innovation, Madrid, Spain
,
Joana GostkorzewiczCelgene SL, Madrid, Spain
,
Patricia BeneditCelgene SL, Madrid, Spain
&
Ferran Pérez-AlcántaraOblikue Consulting SL, Barcelona, SpainCorrespondence[email protected]
 show all
Pages 579-589 | Published online: 19 May 2015

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Briana M. Choi, Rachel B. Abraham, Hala Halawah, Matthias Calamia, Mavis Obeng-Kusi, Neda Alrawashdh, Daniel Arku & Ivo Abraham. (2021) Comparing jurisdiction-specific pharmaco-economic evaluations using medical purchasing power parities. Journal of Medical Economics 24:sup1, pages 34-41.
Read now
Carlo Lazzaro, Carlo Barone, Francesco Caprioni, Stefano Cascinu, Alfredo Falcone, Evaristo Maiello, Michele Milella, Carmine Pinto, Michele Reni & Giampaolo Tortora. (2018) An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics & Outcomes Research 18:4, pages 435-446.
Read now

Articles from other publishers (7)

Diego Hernandez, Fabienne Wagner, Karla Hernandez-Villafuerte & Michael Schlander. (2022) Economic Burden of Pancreatic Cancer in Europe: a Literature Review. Journal of Gastrointestinal Cancer 54:2, pages 391-407.
Crossref
Kosuke Morimoto, Kensuke Moriwaki, Takako Kaneyasu, Hitomi Nakayama & Kojiro Shimozuma. (2022) Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan. Value in Health Regional Issues 28, pages 54-60.
Crossref
Louise Wang, Frank I. Scott, Ben Boursi, Kim A. Reiss, Sankey Williams, Henry Glick & Yu-Xiao Yang. (2021) Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Clinical Gastroenterology and Hepatology.
Crossref
Min Su You, Ji Kon Ryu, Young Hoon Choi, Jin Ho Choi, Gunn Huh, Woo Hyun Paik, Sang Hyub Lee & Yong-Tae Kim. (2018) Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer. Gut and Liver 12:6, pages 728-735.
Crossref
Claire Gérard, Philippe Fagnoni, Angélique Vienot, Christophe Borg, Samuel Limat, Franck Daval, François Calais, Julie Vardanega, Marine Jary & Virginie Nerich. (2017) A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. European Journal of Cancer 86, pages 207-216.
Crossref
Machiko Kurimoto, Michio Kimura, Eiseki Usami, Mina Iwai, Tatsuya Hirose, Shiori Kawachi & Tomoaki Yoshimura. (2017) Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer. Molecular and Clinical Oncology.
Crossref
Mahdi Gharaibeh, J. Lyle Bootman, Ali McBride, Jennifer Martin & Ivo Abraham. (2016) Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. PharmacoEconomics 35:1, pages 83-95.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.